AbbVie Says IRS Can’t Treat $1.6B Break Fee As Capital Loss

The Internal Revenue Service cannot reclassify as a capital loss a $1.6 billion payment AbbVie made to an Irish biotechnology company after their failed merger and thereby raise the pharmaceutical giant’s tax bill by $572 million, the company’s attorneys told the U.S. Tax Court.